BIA
SRPT icon

Bell Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Bell Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30
Closed -$579 – 1940
2025
Q3 		$579 Sell
30
-24
-44% -$428 ﹤0.01% 1718
2025
Q2 		$924 Buy
54
+46
+575% +$1.96K ﹤0.01% 1612
2025
Q1 		$511 Sell
8
-4
-33% -$421 ﹤0.01% 1743
2024
Q4 		$1.46K Buy
12
+8
+200% +$980 ﹤0.01% 1451
2024
Q3 		$500 Hold
4
– – ﹤0.01% 1778
2024
Q2 		$632 Hold
4
– – ﹤0.01% 1737
2024
Q1 		$518 Buy
+4
New +$490 ﹤0.01% 1810
2023
Q3 		– Sell
-8
Closed -$917 – 1991
2023
Q2 		$917 Hold
8
– – ﹤0.01% 1618
2023
Q1 		$1.1K Hold
8
– – ﹤0.01% 1526
2022
Q4 		$1.04K Hold
8
– – ﹤0.01% 1569
2022
Q3 		$1K Sell
8
-53
-87% -$5.34K ﹤0.01% 1578
2022
Q2 		$5K Buy
+61
New +$4.49K ﹤0.01% 740
2021
Q4 		$5K Sell
53
-101
-66% -$8.63K ﹤0.01% 799
2021
Q3 		$14K Buy
+154
New +$11.9K ﹤0.01% 372

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bell Investment Advisors's SRPT Position: Q4 2025 in Review

Bell Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 30 shares — an estimated $579 sold.

Bell Investment Advisors first reported a position in SRPT in Q3 2021 and held it in 14 quarters. The position peaked at $14K in Q3 2021. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Bell Investment Advisors reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 30 Sarepta Therapeutics shares in Q4 2025, an estimated $579.
  • Bell Investment Advisors first reported a position in Sarepta Therapeutics in Q3 2021 and held it in 14 quarters.
  • Bell Investment Advisors's Sarepta Therapeutics position peaked at $14K in Q3 2021.
  • 347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.